

Docket No.: 050193-0109

## PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Customer Number: 20277

Salah D. KIVLIGHN, et al.

Confirmation Number: 4997

Application No.: 09/892,505

Group Art Unit: 1636

•

Filed: June 28, 2001

Examiner: NGUYEN, QUANG

For: TREATMENT FOR CARDIOVASCULAR DISEASE

## INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached form PTO-1449. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

Each non-English language reference was first cited in a corresponding foreign application search report or office action and its relevance discussed therein. A copy of the

09/892,505

foreign search report or office action, together with an English language version thereof, is

attached for the Examiner's information.

Please charge any shortage in fees due in connection with the filing of this paper,

including extension of time fees, to Deposit Account 500417 and please credit any excess fees to

such deposit account.

Respectfully submitted,

MeDERMOTT WILL & EMERY LLP

Judith L. Toffenetti Registration No. 39,048

600 13th Street, N.W.

Washington, DC 20005-3096 Phone: 202.756.8000 JLT:gav Facsimile: 202.756.8087

Date: March 23, 2005

Please recognize our Customer No. 20277 as our correspondence address.

2



SHEET 1 OF 1

INFC	CIT	'nΤ	ION DISCLOS ION IN AN LICATION	SUKE	050193-0109		09/892,505		
					APPLICANT Salah D. KIVLIGHN, et al.				
(PTO-1449)					FILING DATE				
		(	,		June 28, 2001	1636			
			U	.S. PATENT	DOCUMENTS				
EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code2 (# Income)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US							
		US					-		
	<del></del>	US							
		US					Ĺ		
		US							
	<u> </u>	US			-		-		
		US							
		US							
		US							
	<u> </u>	US							
		US			-				
				FOREIGN PAT	ENT DOCUMENTS				
EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes -Number 4 -Kind Codes (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear		Yes	anslation No
/3.K./			GB 1 451 029	09/29/1976	MERCK & CO. INC.			Х	
/S.K./			EP 0 337 350 A2	10/18/1989	EISAI CO., LTD.			X	
		_							
	<del> </del>	$\vdash$							
	<b></b>								
					, Title, Date, Pertinent Pages, E				
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
/S.K./		MIYAMOTO, Y., et al. "Potentiation of nitric oxide-mediated vasorelaxation by xanthine oxidese inhibitors.", Proceedings of the Society for Experimental Biology and Medicine, April 1996, Volume 211, NR 4, PG 386-373							
			AMINER		44/00/	DATE CONSIL	DERED		1
/Sho	obha K	anta	mneni/		11/20/2008				

\*EXAMINER: Initial Treference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not conside include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.